Literature DB >> 19462484

Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA.

Christoph J Zech1, Bernhard Vos, Anders Nordell, Matthias Urich, Lennart Blomqvist, Josy Breuer, Maximilian F Reiser, Hanns-Joachim Weinmann.   

Abstract

OBJECTIVES: To investigate the influence of 2 different doses and injection rates on the enhancement of liver vasculature in Gd-EOB-DTPA enhanced liver MRI compared with the standard dose Gd-DTPA.
MATERIALS AND METHODS: This animal experimental study has been approved by the local authorities. In 5 pigs, a time-resolved T1w 3D GRE sequence, and in a second experiment, a single-slice turbo FLASH T1w sequence with 3 frames/s were started each with contrast agent application of Gd-EOB-DTPA and Gd-DTPA. Three sets with different doses were performed with an injection rate of 1 and 2 mL/s which are as follows: A, Standard dose: 25 [mu]mol Gd-EOB-DTPA/kg body-weight (bw); B, Double dose: 50 [mu]mol Gd-EOB-DTPA/kg bw; and C, Standard dose: 100 [mu]mol Gd-DTPA/kg bw. Signal intensities were measured in aorta, vena cava inferior, portal vein, and liver parenchyma, and time-signal-to-noise (SNR)-curves were generated. The increase in SNR from baseline and several perfusion parameters were calculated. Statistical significance was tested with the Wilcoxon rank test at a significance level of P = 0.05.
RESULTS: Mean peak enhancement (SNR) in the aorta was not significantly different for set A, B, and C with the same injection rate. Mean peak enhancement in the aorta was significantly higher for set A at 1 mL/s than at 2 mL/s (159.1 vs. 144.4, P = 0.043). Mean peak enhancement in the PV, the vena cava inferior, and the liver parenchyma was significantly lower for set A compared with set B and set C, at both injection speeds. The full width at half max was significantly longer for injection protocols with 1 as compared with 2 mL/s for sets A and set B. Set A with 1 mL/s reached similar values as compared with set C with 2 mL/s for the full width at half max (8.92 vs. 9.40; P = 0.35), for the area-under-the curve (1736.64 vs. 1912.74; P = 0.69) and the maximal signal-to-noise ratio (25.21 vs. 25.37; P = 0.69).
CONCLUSION: Despite the lower amount of gadolinium in the standard dose of Gd-EOB-DTPA, the results showed that the arterial enhancement in Gd-EOB-DTPA-enhanced dynamic liver MRI was comparable to Gd-DTPA. This result can be explained mainly by the higher relaxivity. Choosing a lower injection rate additionally supported to compensate for the lower injection volume by stretching the bolus without decreasing the peak. In this respect, an injection rate of 1 mL/s showed better results with regard to the arterial enhancement compared with 2 mL/s.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19462484     DOI: 10.1097/rli.0b013e3181a24512

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  26 in total

1.  Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

Authors:  J Hwang; S H Kim; M W Lee; J Y Lee
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

2.  The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.

Authors:  Carmen Ayuso; Jordi Bruix
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

3.  Modified CAIPIRINHA-VIBE without view-sharing on gadoxetic acid-enhanced multi-arterial phase MR imaging for diagnosing hepatocellular carcinoma: comparison with the CAIPIRINHA-Dixon-TWIST-VIBE.

Authors:  Seung Baek Hong; Nam Kyung Lee; Suk Kim; Hyeong Il Seo; Hyun Sung Kim; Dong Uk Kim; Tae Un Kim; Hwa Seong Ryu
Journal:  Eur Radiol       Date:  2019-04-16       Impact factor: 5.315

4.  Time-intensity curve in the abdominal aorta on dynamic contrast-enhanced MRI with high temporal and spatial resolution: Gd-EOB-DTPA versus Gd-DTPA in vivo.

Authors:  Yasunari Fujinaga; Hitoshi Ueda; Yoshihiro Kitou; Yoshinori Tsukahara; Yukiko Sugiyama; Masumi Kadoya
Journal:  Jpn J Radiol       Date:  2012-11-20       Impact factor: 2.374

Review 5.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

6.  An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.

Authors:  Utaroh Motosugi; Peter Bannas; Candice A Bookwalter; Katsuhiro Sano; Scott B Reeder
Journal:  Radiology       Date:  2015-10-16       Impact factor: 11.105

7.  Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients.

Authors:  Bang-Bin Chen; Chao-Yu Hsu; Chih-Wei Yu; Shwu-Yuan Wei; Jia-Horng Kao; Hsuan-Shu Lee; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2011-08-31       Impact factor: 5.315

8.  [Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria].

Authors:  A Kircher; G Bongartz; E M Merkle; C J Zech
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

Review 9.  Hepatobiliary MR imaging with gadolinium-based contrast agents.

Authors:  Alex Frydrychowicz; Meghan G Lubner; Jeffrey J Brown; Elmar M Merkle; Scott K Nagle; Neil M Rofsky; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-03       Impact factor: 4.813

10.  Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma.

Authors:  Hanke J Schalkx; Marijn van Stralen; Kenneth Coenegrachts; Maurice A A J van den Bosch; Charlotte S van Kessel; Richard van Hillegersberg; Karel J van Erpecum; Helena M Verkooijen; Josien P W Pluim; Wouter B Veldhuis; Maarten S van Leeuwen
Journal:  Eur Radiol       Date:  2014-07-05       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.